ReviewFrontiers in oncology2023

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer.

Remziye Zaim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.